Aspire Biopharma Holdings, Inc.

Aspire Biopharma Holdings, Inc. (Nasdaq: PWUP) filed an 8-K with the Securities and Exchange Commission on May 14, 2026, continuing its public reporting obligations in the biopharmaceutical sector. The company operates under the PWUP ticker and is focused on the life sciences and biopharma industry, a segment that has drawn sustained SPAC activity in recent years as sponsors seek exposure to clinical-stage and commercial drug development platforms. The accession number for the filing is 0001493152-26-023069. For complete data on PWUP including sponsor details, deal history, SEC filing timeline, and current status, create a free account at SpacDesk.